See more : Sakata Seed Corporation (1377.T) Income Statement Analysis – Financial Results
Complete financial analysis of Aytu BioPharma, Inc. (AYTU) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Aytu BioPharma, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Harbor Custom Development, Inc. (HCDI) Income Statement Analysis – Financial Results
- American Pacific Rim Commerce Group (APRM) Income Statement Analysis – Financial Results
- China National Complete Plant Import & Export Corporation Limited (000151.SZ) Income Statement Analysis – Financial Results
- California International Bank, N.A. (CAIB) Income Statement Analysis – Financial Results
- Aurelia Metals Limited (AUMTF) Income Statement Analysis – Financial Results
Aytu BioPharma, Inc. (AYTU)
About Aytu BioPharma, Inc.
Aytu Biopharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company offers Adzenys XR-ODT for the treatment of attention deficit hyperactivity disorder (ADHD) in patients from 6 years and older; Cotempla XR-ODT for the treatment of ADHD in patients from 6 to 17 years old; and Adzenys ER, an oral suspension for the treatment of ADHD in patients from 6 years and older. It also provides Karbinal ER, a carbinoxamine oral suspension for the treatment of seasonal and perennial allergies; Poly-Vi-Flor and Tri-Vi-Flor prescription supplements for infants and children for the treatment of fluoride deficiency; Tuzistra XR, a prescription antitussive consisting of codeine polistirex and chlorpheniramine polistirex in an oral suspension; and ZolpiMist, an oral spray for the treatment of insomnia. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu Biopharma, Inc. in March 2021. Aytu Biopharma, Inc. was incorporated in 2015 and is headquartered in Englewood, Colorado.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 81.00M | 107.40M | 96.67M | 65.63M | 27.63M | 7.32M | 3.66M | 3.22M | 2.56M | 261.78K | 58.93K | 1.75K | 1.75K | 0.00 | 0.00 | 1.75K | 0.00 | 0.00 |
| Cost of Revenue | 26.42M | 40.77M | 44.39M | 36.43M | 7.55M | 2.20M | 2.05M | 1.42M | 957.08K | 88.11K | 0.00 | -48.25K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 54.59M | 66.63M | 52.28M | 29.20M | 20.08M | 5.12M | 1.61M | 1.80M | 1.61M | 173.67K | 58.93K | 50.00K | 1.75K | 0.00 | 0.00 | 1.75K | 0.00 | 0.00 |
| Gross Profit Ratio | 67.39% | 62.04% | 54.08% | 44.49% | 72.67% | 69.92% | 43.97% | 56.00% | 62.65% | 66.34% | 100.00% | 2,857.14% | 100.00% | 0.00% | 0.00% | 100.00% | 0.00% | 0.00% |
| Research & Development | 2.79M | 4.10M | 14.44M | 5.62M | 1.72M | 589.07K | 167.60K | 1.35M | 6.32M | 3.42M | 4.06M | 2.76M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 22.51M | 28.63M | 31.17M | 25.50M | 19.66M | 0.00 | 17.73M | 17.61M | 8.83M | 4.38M | 2.35M | 47.98K | 58.11K | 129.37K | 54.16K | 54.86K | 54.98K | 0.00 |
| Selling & Marketing | 26.96M | 41.45M | 38.71M | 30.31M | 11.40M | 0.00 | 0.00 | -242.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 49.47M | 70.08M | 69.88M | 55.81M | 34.80M | 19.24M | 17.73M | 17.61M | 8.83M | 4.38M | 2.35M | 47.98K | 58.11K | 129.37K | 54.16K | 54.86K | 54.98K | 46.89K |
| Other Expenses | 7.58M | -4.78M | 4.07M | 6.01M | 4.49M | 2.14M | 6.28M | 1.71M | 664.71K | 4.89K | 6.18K | 6.18K | 7.34K | 4.25K | 2.58K | 2.71K | 0.00 | 0.00 |
| Operating Expenses | 60.57M | 78.96M | 88.39M | 67.44M | 41.01M | 21.96M | 19.45M | 20.66M | 15.81M | 7.81M | 6.41M | 54.16K | 58.11K | 133.62K | 56.74K | 57.57K | 54.98K | 46.89K |
| Cost & Expenses | 86.26M | 119.73M | 132.77M | 103.87M | 48.57M | 24.17M | 21.50M | 22.08M | 16.77M | 7.89M | 6.41M | 54.16K | 58.11K | 133.62K | 56.74K | 57.57K | 54.98K | 46.89K |
| Interest Income | 0.00 | 9.00K | 14.00K | 6.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 4.79M | 0.00 | 147.50M | 0.00 | 0.00 | 0.00 | 749.42K | 2.53M | 5.49M | 114.99K | 45.55K | 4.90K | 3.32K | 3.18K | 3.80K | 3.07K | 0.00 | 2.06K |
| Depreciation & Amortization | 8.27M | 8.82M | 10.15M | 7.70M | 4.59M | 2.24M | 1.85M | 1.84M | 874.79K | 118.20K | 97.48K | 4.94K | 6.15K | 6.76K | 9.19K | 8.28K | 7.52K | 6.42K |
| EBITDA | -1.01M | -3.51M | -27.96M | -29.04M | -12.21M | -14.12M | -15.25M | -18.13M | -21.81M | -7.51M | -52.71K | -47.47K | -50.21K | -126.86K | -47.28K | -47.54K | -47.47K | -40.47K |
| EBITDA Ratio | -1.25% | -7.07% | 42.70% | -22.08% | -89.07% | -59.69% | -245.22% | -449.95% | -520.19% | -2,870.37% | -10,604.89% | -2,712.69% | -2,868.91% | 0.00% | 0.00% | -2,716.51% | 0.00% | 0.00% |
| Operating Income | -5.25M | -17.07M | 37.22M | -38.24M | -20.94M | -16.85M | -19.70M | -20.13M | -21.70M | -7.63M | -6.35M | -52.41K | -56.36K | -133.62K | -56.74K | -55.82K | -54.98K | -46.89K |
| Operating Income Ratio | -6.49% | -15.89% | 38.50% | -58.26% | -75.76% | -230.13% | -538.26% | -624.70% | -847.02% | -2,915.53% | -10,770.31% | -2,995.09% | -3,220.34% | 0.00% | 0.00% | -3,189.83% | 0.00% | 0.00% |
| Total Other Income/Expenses | -8.82M | 14.00K | 1.02M | 840.00K | 7.51M | -10.29M | 9.51M | -2.38M | -6.48M | -114.99K | -4.23K | -4.90K | -3.32K | -3.18K | -3.53K | -3.07K | -2.19K | -2.06K |
| Income Before Tax | -14.08M | -17.05M | -110.28M | -58.03M | -13.62M | -27.13M | -10.19M | -22.51M | -28.18M | -7.75M | -6.39M | -57.32K | -59.68K | -136.80K | -56.47K | -58.89K | -48.95K | -48.95K |
| Income Before Tax Ratio | -17.38% | -15.88% | -114.08% | -88.42% | -49.29% | -370.64% | -278.36% | -698.67% | -1,099.73% | -2,959.45% | -10,847.61% | -3,275.31% | -3,410.00% | 0.00% | 0.00% | -3,365.37% | 0.00% | 0.00% |
| Income Tax Expense | 1.77M | -57.00K | -110.00K | 259.00K | -9.92M | 20.04M | -2.13M | 1.11M | 8.48M | -23.91K | -813.70K | 911.31K | 3.32K | 3.18K | -548.00 | 3.07K | 2.19K | 2.06K |
| Net Income | -15.84M | -17.05M | -108.78M | -58.29M | -13.62M | -47.17M | -10.19M | -22.51M | -28.18M | -7.72M | -5.58M | -57.32K | -59.68K | -136.80K | -60.27K | -58.89K | -57.17K | -48.95K |
| Net Income Ratio | -19.56% | -15.88% | -113.97% | -88.81% | -13.39% | -644.33% | -278.36% | -698.67% | -1,099.73% | -2,950.32% | -9,466.80% | -3,275.31% | -3,410.00% | 0.00% | 0.00% | -3,365.37% | 0.00% | 0.00% |
| EPS | -2.86 | -5.11 | -74.01 | -69.60 | -60.20 | -1.21K | -3.06K | -193.19K | -1.29M | -551.67K | -619.85K | -7.16K | -7.46K | -17.10K | -10.05K | -11.78K | -11.43K | -48.95K |
| EPS Diluted | -2.86 | -5.11 | -74.01 | -69.60 | -60.20 | -1.21K | -3.06K | -193.19K | -1.29M | -551.67K | -619.85K | -7.16K | -7.46K | -17.10K | -10.05K | -11.78K | -11.43K | -48.95K |
| Weighted Avg Shares Out | 5.54M | 3.34M | 1.47M | 840.00K | 230.00K | 38.97K | 3.33K | 116.51 | 21.77 | 14.00 | 9.00 | 8.00 | 8.00 | 8.00 | 6.00 | 5.00 | 5.00 | 1.00 |
| Weighted Avg Shares Out (Dil) | 5.54M | 3.34M | 1.47M | 840.00K | 230.00K | 38.97K | 3.33K | 116.51 | 21.77 | 14.00 | 9.00 | 8.00 | 8.00 | 8.00 | 6.00 | 5.00 | 5.00 | 1.00 |
Aytu BioPharma Announces Peer-Reviewed Publication of Clinical Results from Healight(TM) Pilot Study
Results Indicate That Endotracheal UVA Light Catheter Therapy is Associated with Significant Reduction in SARS-CoV-2 Viral Load and Improvement in Clinical Outcomes in Mechanically Ventilated COVID-19 Patients ENGLEWOOD, CO / ACCESSWIRE / June 28, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU),...
Technical Levels To Watch In Aytu BioPharma Stock
Aytu BioPharma Inc. (NASDAQ: AYTU) shares were rallying Monday after retail traders were able to push the stock higher. The stock has traded on above-average volume with 7.6 million shares traded so far — over 1,000% its average volume over the last...
What's Next For Aytu BioPharma Stock As It Gaps Up To Resistance?
Aytu BioPharma Inc. (NASDAQ: AYTU) shares saw a gap up Tuesday morning as retail traders tried to push the stock higher. The stock saw a sizable premarket move and opened at $6.15, but has since fallen back near the $5.70...
Aytu BioPharma to Present at Upcoming June Investor Conferences
ENGLEWOOD, CO / ACCESSWIRE / May 25, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, announced today that Josh Disbrow, Chairman and Chief Executive Officer, will present at two...
Aytu Biopharma, Inc. (AYTU) CEO Joshua Disbrow on Q3 2021 Results - Earnings Call Transcript
Aytu Biopharma, Inc. (AYTU) CEO Joshua Disbrow on Q3 2021 Results - Earnings Call Transcript
Recap: Aytu BioPharma Q3 Earnings
Shares of Aytu BioPharma (NASDAQ:AYTU) decreased in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share fell 186.67% year over year to ($0.43), which missed the estimate of ($0.31).
Aytu BioPharma Reports Fiscal Third Quarter 2021 Financial Results and Recent Business Highlights
- Closed merger with Neos Therapeutics creating a proforma combined $100 million revenue specialty pharmaceutical company - - Added late-stage pediatric onset rare disease asset, protein kinase C β isoform (PKCβ) inhibitor, AR101 (enzastaurin) to development pipeline - - Record...
Aytu BioPharma Announces Publication of In Vitro Study Demonstrating That Ultraviolet-A Light Increases Mitochondrial Anti-Viral Signaling Protein Within Cells
ENGLEWOOD, CO / ACCESSWIRE / May 12, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, announced today that in vitro data related to the ultraviolet (UV) A light used...
Aytu BioPharma to Report Third Quarter Fiscal 2021 Results on May 17, 2021
ENGLEWOOD, CO / ACCESSWIRE / May 10, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, announced today that it will host a conference call and live webcast on Monday,...
Aytu BioPharma Adds Late-Stage Pediatric Onset Rare Disease Asset to Development Pipeline from Rumpus Therapeutics
Aytu gains global license to pivotal study-ready protein kinase C β isoform (PKCβ) inhibitor, AR101 (enzastaurin) in rare disease indications Program initially targeting vascular Ehlers-Danlos Syndrome (vEDS), a rare inherited connective tissue disorder resulting in high morbidity and a significantly...
Source: https://incomestatements.info
Category: Stock Reports